Introduction
============

Epstein--Barr virus (EBV), a member of the human herpesvirus family, is an oncogenic virus that infects lymphoid and epithelial cells. Although EBV normally remains latent after infecting B lymphocyte cells, the virus must enter the lytic cycle to proliferate and produce infectious particles. The pivotal role of the two EBV intermediate-early proteins, Replication and transcription activator (Rta) and Zta, in activating the transcription of EBV lytic genes is well-documented ([@B35]; [@B45]; [@B23]; [@B1]). In previous studies, we showed that Rta is conjugated to SUMO-1 by Ubc9 and PIAS (protein inhibitor of activated STAT) proteins, and this sumoylation enhances Rta transactivation activity ([@B10]). Rta is also modified by SUMO-2 ([@B18]), and can be ubiquitinated via the SUMO chain by a SUMO-targeted E3 ubiquitin ligase, RNF4, thereby inhibiting EBV lytic activation ([@B43]).

In this study, we identified a second E3 ubiquitin ligase that promotes Rta ubiquitination to influence EBV lytic progression, TRIM5α. TRIM5α is a member of the tripartite motif (TRIM) protein superfamily, and acts as a host restriction factor that limits retroviral infection ([@B36]; [@B27]). Earlier studies have shown that TRIM5α from rhesus macaques (rhTRIM5α) restricts early events in human immunodeficiency virus (HIV)-1 infection, while human TRIM5α restricts infection by N-tropic murine leukemia virus (N-MLV) ([@B44]). As an intrinsic immunity protein, TRIM5α catalyzes the synthesis of unanchored K63-linked polyubiquitin chains, and then activates NF-κB or AP-1 dependent transcription ([@B27]). TRIM5α contains B boxes, a coiled-coil domain, and a RING domain, and can function as an E3 ubiquitin ligase ([@B29]). In addition, TRIM5α contains a SPRY/B30.2 domain with two SUMO-interaction motifs (SIMs), which are required for N-MLV restriction ([@B2]). This SPRY/B30.2 domain can also directly bind with the HIV capsid, and is believed to be critical for HIV restriction ([@B31]; [@B37]; [@B24]; [@B16]). Moreover, TRIM5α-mediated ubiquitin conjugation is required for HIV-1 capsid destabilization and inhibition of reverse transcription ([@B7]). Interestingly, SIM mutations in TRIM5α not only lead to loss of restriction capability against N-MLV ([@B2]), but the mutations also prevent TRIM5α from shuttling into the cell nucleus, thus rendering it unable to restrict incoming HIV retrovirion cores ([@B4]).

Although TRIM5α primarily acts to limit the propagation of retroviruses ([@B17]; [@B21]; [@B26]; [@B36]; [@B44]), it has been reported that rhTRIM5α can hamper the replication of herpes simplex virus (HSV) ([@B28]), a double-stranded DNA virus. In this study, we identified an interaction between TRIM5α and the EBV viral protein, Rta, using GST-pulldown and coimmunoprecipitation assays. TRIM5α and Rta colocalized in the nucleus, and we further found that TRIM5α can act as an E3 ubiquitin ligase that promotes Rta ubiquitination. This subsequently leads to the downregulation of Rta transactivation capabilities, indicating that TRIM5α may play a critical role in attenuating EBV lytic progression. These results suggest that the restrictive abilities of TRIM5α are not limited to retroviruses, and may have interesting implications for antiviral research and development.

Materials and Methods {#s1}
=====================

Cell Lines and EBV Lytic Induction
----------------------------------

P3HR1, a Burkitt's lymphoma cell line latently infected by EBV ([@B3]), was cultured in RPMI1640 medium containing 10% fetal calf serum. 293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum. P3HR1 cells were treated with 30 ng/mL 12-*O*-tetradecanoylphorbol-13-acetate (TPA) and 3 mM sodium butyrate to activate the EBV lytic cycle ([@B25]; [@B14]; [@B11]).

Plasmids
--------

Plasmids pGEX-TRIM5α and pEGFP-TRIM5α were constructed by inserting a DNA fragment, which was amplified by PCR using pLPCX-TRIM5α as a template (NIH AIDS reagent program, USA) and the primers TRIM5α-F (5′-CCGGAATTCATGGCTTCTGGAATCCTGGT) and TRIM5α-R (5′-ACGCGTCGACTCAAGAGCTTGGTGAGCACA), into the *Eco*RI and *Sal*I sites in pGEX-4T1 (Amersham) and pEGFP-C2 (Clontech), respectively. DNA fragments, which encode the regions in TRIM5α from amino acids 1 to 261, 81 to 493, and 261 to 493 were amplified by PCR. These DNA fragments were then inserted into the *Eco*RI and *Sal*I sites in pEGFP-C2 to generate pEGFP-TRIM5α-dC, pEGFP-TRIM5α-dN, and pEGFP-TRIM5α-dNM, respectively. The DNA fragment from amino acids 1 to 261 was also inserted into pTag2B to create pFlag-TRIM5α-dC. Plasmids that express deletion mutants of GFP-Rta, including GFP-N190, GFP-N191/415, and GFP-Rev have been described previously ([@B20]; [@B8]; [@B42]). Plasmids pFlag-Ub, pFlag-Rta, and pET-Rta, which express Flag-tagged ubiquitin, Flag-tagged Rta and His-tagged Rta, were described earlier ([@B43]). For transient transfection assays, the reporter plasmid, pBMRF1, was constructed by inserting a PCR-amplified DNA fragment containing the -172 to +20 region in BMRF1 into pGL2-Basic ([@B8]). Plasmid pBMLF1-RRE containing the RRE sequence from the BMLF1 promoter and a TATA sequence was synthesized and inserted into pGL2-Basic ([@B10]). Similarly, the RRE sequence from the BMRF1 promoter and a TATA sequence was synthesized and inserted into pGL2-Basic to generate pBMRF1-RRE.

MALDI-TOF Mass Spectrometry
---------------------------

P3HR1 cells were treated with TPA and sodium butyrate for 24 h to activate the EBV lytic cycle and Rta expression. Cells were harvested by low speed centrifugation and lysed using mRIPA buffer (50 mM Tris-HCl (pH 7.8), 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5% Nonidet P-40), and proteins in the lysate were immunoprecipitated using anti-Rta antibody and protein A/G-agarose beads (Millipore). The beads were washed with mRIPA buffer for three times, and proteins on the beads were then extracted with electrophoresis sample buffer (10% glycerol, 60 mM Tris-HCl pH 6.8, 2% SDS, 2.5% β-mercaptoethanol, 2 mM EDTA) and subjected to 2-D polyacrylamide gel electrophoresis. Proteins in the gel were stained with Coomassie blue, and prospective protein spots in the gel were then excised. The proteins in the spots were digested with trypsin according to an in-gel digestion protocol ([@B33]), and the resulting peptides were analyzed using a Bruker Biflex III MALDI-TOF mass spectrometer (Bruker Daltonics) ([@B40]). The m/z ratios of the digested peptides and their fragmented ions were used to search the annotated human genome in the Mass Spectrometry protein sequence Database (MSDB), using Mascot search software v1.8 (Matrix Science Inc). The search criteria used were as follows: maximum of one missed trypsin cleavage; variable modification, including carbamidomethylation; and 1 Da peptide mass tolerance. Only proteins identified as significant hits (*p* \< 0.05) by Mascot peptide mass fingerprint search were selected.

Protein Expression and GST Pulldown Assay
-----------------------------------------

*Escherichia coli* BL21(DE3)(pGEX-TRIM5α) and *E. coli* BL21(DE3)(pGST) were cultured to the mid-log phase and then treated with 0.1 mM isopropyl β-[[[D]{.smallcaps}]{.smallcaps}]{.smallcaps}-1-thiogalactopyranoside (IPTG) to, respectively, induce the expression of GST-TRIM5α and GST according to a method described earlier ([@B10]). GST and GST-TRIM5α were purified from bacterial lysates using glutathione-Sepharose 4B beads (GE healthcare).

Transient Transfection and Luciferase Assay
-------------------------------------------

293T cells were transfected with plasmids using Turbofect (Thermo Fisher Scientific), according to the method recommended by the manufacturer. At 24--48 h after transfection, cells were harvested and lysed using mRIPA lysis buffer \[50 mM Tris-HCl (pH 7.8), 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5% Nonidet P-40\]. Luciferase assays were performed according to a method described earlier ([@B12]).

Coimmunoprecipitation of Rta and TRIM5α
---------------------------------------

293T cells were transfected with pCMV-Rta and pHA-TRIM5α, and at 24 h after transfection, cells were collected and lysed in mRIPA buffer. Proteins in the lysate were immunoprecipitated with anti-Rta and anti-HA antibodies. Protein A/G-agarose beads were then added to the lysate, and proteins bound to the beads were subsequently analyzed by immunoblotting. To detect ubiquitinated proteins, 293T cells were cotransfected with pCMV-R, pTag-2B, and pLPCX-TRIM5α. At 24 h after transfection, cells were treated with 5 μM MG132 for additional 12 h. Cells were harvested according to a method described earlier ([@B10]; [@B43]) to detect ubiquitin-conjugated proteins.

Immunoblot Analysis
-------------------

Proteins were separated in SDS-polyacrylamide gels and then electrotransferred to Hybond C membranes (GE) at 90 V for 1 h, according to a method described elsewhere ([@B10]). The membrane was then probed with the appropriate antibodies, including anti-Rta (Argene), anti-TRIM5α (Santa Cruz), anti-HA (Roche), anti-GFP (Santa Cruz), anti-GST (Santa Cruz), anti-VCA (Argene), anti-BFRF3 ([@B39]), and anti-α-tubulin (Sigma) antibodies.

Immunofluorescence Analysis
---------------------------

P3HR1 cells were treated with sodium butyrate and TPA for 24 h, harvested by centrifugation, plated on poly-[[[L]{.smallcaps}]{.smallcaps}]{.smallcaps}-lysine (Sigma)-coated coverslips, and fixed with 4% paraformaldehyde in PBS for 30 min. Immunostaining was conducted using anti-Rta monoclonal antibodies (Argene) and anti-TRIM5α polyclonal antibodies (Santa Cruz). Cells were then treated with Alexa Fluor^®^ 594 goat anti-mouse and Alexa Fluor^®^ 488 goat anti-rabbit antibodies (Invitrogen). Nuclei were visualized by staining with 5 mg/mL 4′-6-diamidino-2-phenylindole (DAPI). Cells were observed under a confocal laser scanning microscope (Leica TCS SP8).

Knockdown of TRIM5α Expression
------------------------------

TRIM5α shRNA and plasmids, including pMD2.G, pCMVDR8.91, and pLKO-shRNA, were purchased from the National RNAi Core Facility, Genomic Research Center, Academia Sinica, Taipei, Taiwan. 293T cells (2 × 10^5^) were cotransfected with plasmids expressing TRIM5α shRNA (target sequence: 5′-CCAGACATTTGTGAATTTCAA-3′; 2.25 μg), helper plasmids pMD2.G (0.25 μg) and pCMVDR8.91 (2.25 μg), using Turbofect *in vitro* transfection reagent (Thermo Fisher Scientific). Culture media was changed on the following day, and after an additional 24 h, viral supernatants were collected and filtered (0.22 μM), then stored at -80°C. Plasmid pLKO-shRNA was used as a negative control. For lentivirus infection, P3HR1 cells (3 × 10^5^/mL) were transduced with the generated lentiviruses, together with 5 μg/mL of polybrene. Infected P3HR1 cells were selected using 2 μg/mL puromycin in culture medium to produce stable cell lines according to the protocol^[1](#fn01){ref-type="fn"}^.

Determining Copy Numbers of EBV DNA
-----------------------------------

P3HR1 cells were treated with TPA and sodium butyrate to induce the lytic cycle. After 5 days of culturing, virus particles released into the medium were collected by ultracentrifugation at 25,000 × *g* for 2.5 h. EBV copy numbers were determined according to a method described previously ([@B30]; [@B13]). A standard curve was established using maxi-EBV DNA purified from *E. coli* after qPCR analysis. The amounts of EBV DNA purified from the virus in the culture medium were similarly analyzed and compared with the standard curve.

Results
=======

Identification of Cellular Proteins Interacting with Rta
--------------------------------------------------------

We treated P3HR1 cells with TPA and sodium butyrate for 24 h to activate the EBV lytic cycle and allowed the expression of Rta. Proteins interacting with Rta were then coimmunoprecipitated from cell lysates, using anti-Rta antibodies. A similar immunoprecipitation experiment was conducted using anti-IgG antibody as a control. Afterward, 2-D polyacrylamide gel electrophoresis of the immunoprecipitated proteins from each experiment (**Figure [1A](#F1){ref-type="fig"}**) was conducted, and the gels were then stained with Coomassie blue and compared. The comparison results revealed 14 protein spots that appeared in the gel containing anti-Rta immunoprecipitated proteins, but not in the control gel (**Figure [1A](#F1){ref-type="fig"}**). After digesting the proteins in these spots with trypsin, the resulting peptides were analyzed by MALDI-TOF mass spectrometry. The results revealed that five protein spots had peptide fingerprints matching those in the MSDB database (**Figure [1B](#F1){ref-type="fig"}**). Among these, Spot D21 had a protein with a fingerprint matching that of TRIM5α (**Figure [1C](#F1){ref-type="fig"}**), a known E3 ubiquitin ligase that promotes protein ubiquitination. Since Rta is known to be modified by ubiquitin ([@B43]), this study further sought to investigate whether TRIM5α influences the ubiquitination status and functions of Rta.

![**MALDI-TOF mass spectrometry analysis of proteins that interact with Rta. (A)** P3HR1 cells were treated with TPA and sodium butyrate for 24 h to induce the EBV lytic cycle and Rta expression. Cells were then lysed, and proteins in the lysate were immunoprecipitated (IP) with anti-Rta or anti-IgG antibodies. Immunoprecipitated proteins were denatured and analyzed by 2-D polyacrylamide gel electrophoresis. **(B)** Proteins in prospective spots were digested with trypsin and analyzed by MALDI-TOF mass spectrometry. Proteins with peptide fingerprints matching those in the MSDB database are listed in the table at right. **(C)** Peptide sequences in TRIM5α matching those in the D21 proteins are underlined.](fmicb-07-02129-g001){#F1}

Rta Interacts with TRIM5α *In vitro* and *In vivo*
--------------------------------------------------

To verify the interaction between Rta and TRIM5α, we expressed GST-TRIM5α and GST in *E. coli*, and bound these proteins to glutathione-Sepharose beads. GST-TRIM5α-glutathione-Sepharose beads were then added to *E. coli* BL21(DE3)(pET-Rta) lysates, and proteins pulled down by the beads were detected by immunoblotting with anti-Rta antibody. The results revealed that GST-TRIM5α, but not GST-glutathione-Sepharose beads, pulled down Rta (**Figure [2A](#F2){ref-type="fig"}**, lanes 4 and 5), providing *in vitro* evidence of a direct interaction between TRIM5α and Rta. A coimmunoprecipitation experiment using lysates from 293T cells that had been cotransfected with pCMV-Rta and pLPCX-HA-TRIM5α similarly showed that anti-TRIM5α antibody immunoprecipitated HA-TRIM5α and coimmunoprecipitated Rta (**Figure [2B](#F2){ref-type="fig"}**, lanes 4 and 8), while anti-Rta antibody immunoprecipitated Rta and coimmunoprecipitated HA-TRIM5α (**Figure [2B](#F2){ref-type="fig"}**, lanes 3 and 7).

![**Interaction between Rta and TRIM5α. (A)** In a GST-pulldown assay, His-Rta (lanes 3--5) was mixed with GST- (lane 4) and GST-TRIM5α- (lane 5) glutathione-Sepharose beads. Proteins pulled down by the beads were analyzed by immunoblotting (IB) with anti-Rta antibody. Proteins on the glutathione-Sepharose beads (lanes 1 and 2) and Rta in 1% of the lysate (lane 5) were also detected by immunoblotting. **(B)** Coimmunoprecipitation assay results. Anti-Rta and anti-TRIM5α antibodies were added to the lysate from 293T cells that had been transfected with pLPCX-HA-TRIM5α and pCMV-Rta. Lanes 1 and 5 were loaded with 3% of the cell lysate. Proteins immunoprecipitated (IP) with anti-Rta and anti-TRIM5α antibodies or anti-IgG antibody were detected by immunoblotting (IB), using anti-HA (lanes 1--4) and anti-Rta antibodies (lanes 5--8).](fmicb-07-02129-g002){#F2}

Colocalization of TRIM5α with Rta in the Nucleus
------------------------------------------------

The localization of Rta and TRIM5α in P3HR1 cells treated with TPA and sodium butyrate for 24 h was examined by indirect immunofluorescence. Under a confocal laser scanning microscope, we found that both Rta and TRIM5α formed speckles, many of which colocalized in the cell nucleus (**Figures [3f--j](#F3){ref-type="fig"}**). However, Rta was not observed if the cells were not treated with TPA and sodium butyrate (**Figures [3a--e](#F3){ref-type="fig"}**). P3HR1 cells treated with or without TPA and sodium butyrate were also stained with secondary antibodies as a control to demonstrate the specificity of anti-TRIM5α antibody (**Figures [3k--t](#F3){ref-type="fig"}**).

![**Subcellular localization of Rta and TRIM5α.** P3HR1 cells were treated with sodium butyrate and TPA (SB/TPA) or DMSO (NC) for 24 h. Cells were incubated with monoclonal anti-Rta antibody **(c,h)** and polyclonal anti-TRIM5α antibody **(b,g)**. Cells were also stained with secondary antibodies **(k--t)** as a control. Nuclei were visualized by DAPI staining **(a,f)**. Cells were observed under a confocal laser-scanning microscope, and **(d,e,i,j,n,o,s,t)** are merged images. Scale bar indicates 10 μm.](fmicb-07-02129-g003){#F3}

Analysis of Interacting Domains in Rta and TRIM5α
-------------------------------------------------

We cotransfected 293T cells with pFlag-TRIM5α and plasmids expressing different segments of Rta that were fused to GFP (**Figure [4A](#F4){ref-type="fig"}**). Control cells were cotransfected with plasmids expressing GFP and Flag-TRIM5α. Immunoblotting with anti-GFP antibody revealed that GFP and the GFP-Rta fusion proteins were expressed at similar levels after transfection (**Figure [4B](#F4){ref-type="fig"}**, lanes 1--5). Following immunoprecipitation with anti-Flag antibody, precipitated proteins were analyzed by immunoblotting with anti-GFP antibody. Results showed that GFP-N190 (**Figure [4B](#F4){ref-type="fig"}**, lane 8), which contains 190 amino acids from the N-terminal of Rta, was coimmunoprecipitated with Flag-TRIM5α, indicating that this is the region in Rta that interacts with TRIM5α. In addition, we also observed a weak binding effect between TRIM5α and GFP-N191-415 (**Figure [4B](#F4){ref-type="fig"}**, lane 9). However, GFP-Rev was not coimmunoprecipitated by Flag-TRIM5α (**Figure [4B](#F4){ref-type="fig"}**, lane 10). A control experiment showed that Flag-TRIM5α was not coimmunoprecipitated with GFP (**Figure [4B](#F4){ref-type="fig"}**, lane 6). These results were reproduced from at least three independent experiments. To identify the region in TRIM5α that interacts with Rta, we generated plasmids expressing GFP fused to different segments of TRIM5α (**Figure [4C](#F4){ref-type="fig"}**). Following cotransfection of these plasmids with pFlag-Rta to 293T cells, cells were subsequently lysed, and the lysates subjected to immunoprecipitation using anti-Flag antibody (**Figure [4D](#F4){ref-type="fig"}**, lanes 1--5). Immunoblot analysis with anti-GFP antibody revealed that only GFP-TRIM5α and GFP-TRIM5α-dC were coimmunoprecipitated with Flag-Rta (**Figure [4D](#F4){ref-type="fig"}**, lanes 7 and 10). In addition, 293T cells were cotransfected with plasmids encoding GFP-N190 and Flag-TRIM5α-dC, and immunoblot analysis revealed that GFP-N190 in cell lysates (**Figure [4E](#F4){ref-type="fig"}**, lane 3) was immunoprecipitated by anti-Flag antibody (**Figure [4E](#F4){ref-type="fig"}**, lane 3). However, control cells that were cotransfected with plasmids expressing GFP and Flag-TRIM5α-dC revealed that GFP was not coimmunoprecipitated with Flag-TRIM5α-dC (**Figure [4E](#F4){ref-type="fig"}**, lane 2). These results indicate that the N-terminal of Rta interacts with the N-terminal RING domain in TRIM5α.

![**Mapping the interaction domains in Rta and TRIM5α. (A)** Plasmids that expressed GFP fused to different segments of Rta were used to delineate the region in Rta that interacts with TRIM5α. **(B)** 293T cells were cotransfected with pFlag-TRIM5α and plasmids expressing GFP or GFP-Rta fusion proteins (pEGFP-Rta, pEGFP-N190, pEGFP-N191-415, pEGFP-Rev, or pEGFP-C1). Input lanes were loaded with 5% of the lysate (lanes 1--5). Proteins in the lysates were coimmunoprecipitated (IP) with anti-Flag antibody and analyzed by immunoblotting (IB) using anti-GFP antibody (lanes 6--10). **(C)** Plasmids expressing various GFP-TRIM5α fusion proteins (GFP-TRIM5α, GFP-TRIM5α-dN, GFP-TRIM5α-dNM, GFP-TRIM5α-dC) were generated. **(D)** 293T cells were cotransfected with plasmids encoding GFP or GFP-TRIM5α fusion proteins (GFP-TRIM5α, GFP-TRIM5α-dN, GFP-TRIM5α-dNM, GFP-TRIM5α-dC). Input lanes were loaded with 5% of the lysate, and GFP-fusion protein expression levels were detected using anti-GFP antibody (lanes 1--5). Proteins in the lysates were coimmunoprecipitated with anti-Flag antibody and analyzed by immunoblotting using anti-GFP antibody (lanes 6--10). **(E)** 293T cells were cotransfected with pFlag-TRIM5α-dC and plasmids expressing either GFP-N190 or GFP. Input lanes were loaded with 5% of the lysate. Proteins in the lysates were coimmunoprecipitated with anti-Flag antibody and analyzed by immunoblotting using anti-GFP antibody.](fmicb-07-02129-g004){#F4}

TRIM5α Promotes Rta Ubiquitination
----------------------------------

TRIM5α has previously been shown to be an E3 ubiquitin ligase ([@B41]), and the observation of Rta-TRIM5α interaction prompted us to investigate whether TRIM5α can influence Rta ubiquitination. We proceeded to transfect 293T cells with pCMV-Rta alone, or with pCMV-Rta and pFlag-Ub. At 24 h after transfection, cells were treated with MG132, a proteasome inhibitor, to prevent the degradation of Rta. When proteins from the lysates of cells transfected with pCMV-Rta alone were immunoprecipitated using anti-Flag antibody and assessed by immunoblotting with anti-Rta, a single non-specific band of about 95 kDa was detected (**Figure [5A](#F5){ref-type="fig"}**, lane 1), which was also observed in previous studies ([@B10]; [@B43]). In 293T cells cotransfected with pCMV-Rta and pFlag-Ub, low amounts of ubiquitinated Rta were detected after the proteins in the lysates were immunoprecipitated with anti-Flag antibody and assessed by immunoblotting with anti-Rta antibody (**Figure [5A](#F5){ref-type="fig"}**, lane 2). When cells were cotransfected with pCMV-Rta, pFlag-Ub, and 0.3 or 0.6 μg of pLCPX-TRIM5α, ubiquitinated Rta became more prominent (**Figure [5A](#F5){ref-type="fig"}**, lanes 3 and 4), demonstrating that TRIM5α promotes Rta ubiquitination. Subsequently, 293T cells were transfected with TRIM5α shRNA to determine whether this would reduce Rta ubiquitination. In a control experiment, immunoblotting did not detect ubiquitinated Rta in cells that were transfected with pHA-Ub (**Figure [5B](#F5){ref-type="fig"}**, lane 1). Ubiquitinated Rta was also detected in cells that were cotransfected with pFlag-Rta and pHA-Ub (**Figure [5B](#F5){ref-type="fig"}**, lane 2). However, introducing TRIM5α shRNA reduced the amounts of ubiquitinated Rta (**Figure [5B](#F5){ref-type="fig"}**, lanes 3 and 4).

![**Enhancement of Rta ubiquitination by TRIM5α. (A)** 293T cells were cotransfected with plasmids expressing Rta, Flag-ubiquitin, and TRIM5α. Proteins in the lysates were immunoprecipitated (IP) using anti-Flag antibody and assessed by immunoblotting (IB) with anti-Rta antibody. **(B)** 293T cells were cotransfected with plasmids pFlag-Rta, pHA-Ub, and pLKO-shTRIM5α, which encoded Flag-Rta, HA-ubiquitin and shTRIM5α, respectively. Proteins in the lysates were immunoprecipitated (IP) using anti-Flag antibody and analyzed by immunoblotting (IB) with anti-HA antibody. At 24 h after transfection, cells were treated with 5 μM MG132 for additional 12 h to inhibit proteasome degradation. The asterisk indicates a non-specific band, also detected in previous studies ([@B10]; [@B43]). Ub-Rta, ubiquitinated Rta.](fmicb-07-02129-g005){#F5}

Influence of TRIM5α on Rta Transactivation Activity
---------------------------------------------------

It is known that Rta acts as a key immediate-early protein that transactivates viral lytic genes to move EBV into the lytic cycle. Therefore, we sought to evaluate the impact of enhanced TRIM5α expression and Rta ubiquitination on the transactivation capabilities of Rta. In a transient transfection assay, we examined how TRIM5α expression can influence Rta transactivation of the EBV BMRF1 promoter, using a luciferase reporter plasmid, pBMRF1 ([@B10]). After cotransfecting 293T cells with pCMV-Rta and pBMRF1, Rta transactivation of BMRF1 was measured by luciferase activity, and the values were taken as 100% (**Figure [6A](#F6){ref-type="fig"}**). We further included 0.1--0.4 μg of pLPCX-TRIM5α in cotransfections, and found that enhanced expression of TRIM5α gradually reduced BMRF1 promoter activation in a dose-dependent manner to just 37--80% (**Figure [6A](#F6){ref-type="fig"}**). A similar experiment also showed that cotransfection of pLPCX-TRIM5α similarly disrupted the ability of Rta to transactivate the BMRF1-RRE (**Figure [6B](#F6){ref-type="fig"}**) and BMLF1-RRE (**Figure [6C](#F6){ref-type="fig"}**) promoters, which contain Rta-responsive elements (RREs). These results show that overexpression of TRIM5α decreases Rta transactivation capability.

![**Reduction of Rta transactivation activity by TRIM5α.** 293T cells were cotransfected with pCMV-R, pLPCX-TRIM5α, and **(A)** pBMRF1, **(B)** pBMRF1-RRE, or **(C)** pBMLF1-RRE. Luciferase activities were assessed 24 h after transfection. Each transfection experiment was performed three times, and each sample in the experiment was prepared in duplicate. Rta, TRIM5α, and α-tubulin expressed by the cells were examined by immunoblotting (IB). The data obtained from the reporter assay were subjected to one-way analysis of variance (ANOVA) using SPSS software 12.0. *P*-values of \<0.05 were considered statistically significant. RLU, relative light units.](fmicb-07-02129-g006){#F6}

Influence of TRIM5α on the Expression of EBV Lytic Proteins and Virion Production
---------------------------------------------------------------------------------

P3HR1 cells were infected with lentivirus expressing TRIM5α shRNA or control shRNA, and cells were then treated with TPA and sodium butyrate to activate the EBV lytic cycle. We found that, compared with cells infected with control shRNA, infection by lentivirus expressing TRIM5α shRNA caused cells to express less TRIM5α, but more Rta and EA-D (**Figure [7A](#F7){ref-type="fig"}**). The expression of TRIM5α shRNA also led to increases in the expression of two EBV capsid proteins, VCA and BFRF3 (**Figure [7B](#F7){ref-type="fig"}**). Quantitative PCR results showed that after lytic activation of P3HR1 cells infected with lentivirus expressing control shRNA, viral yield was estimated at 3 × 10^5^ EBV particles. However, for cells infected with lentivirus expressing TRIM5α shRNA, viral yields increased 400% to 1.2 × 10^6^ viral particles (**Figure [7C](#F7){ref-type="fig"}**). These results showed that TRIM5α expression serves to attenuate EBV lytic development.

![**Influence of TRIM5α on EBV lytic progression. (A)** P3HR1 cells were infected by lentivirus expressing TRIM5α shRNA (shTRIM5α) or control shRNA (Ct-shRNA). Thereafter, cells were treated with sodium butyrate and TPA (SB/TPA) for 48 h, and proteins in the lysates were examined by immunoblotting with anti-Rta, anti-EA-D, anti-TRIM5α, and anti-α-tubulin antibodies. **(B)** Cells were lysed at 120 h after TPA and sodium butyrate treatment, and the expression of VCA, BFRF3, and α-tubulin was examined by immunoblotting. **(C)** An EBV lytic DNA replication assay was conducted by qPCR to determine the copy numbers of EBV DNA. The amount of EBV DNA was determined by standard curve, which was in turn established using maxi-EBV DNA purified from *E. coli* after qPCR analysis. The data were subjected to one-way analysis of variance (ANOVA) using SPSS software 12.0. *P*-values of \<0.05 were considered statistically significant.](fmicb-07-02129-g007){#F7}

Discussion
==========

Rta is a key immediate-early viral protein that is responsible for activating the transcription of EBV lytic genes, thereby triggering the viral lytic cascade ([@B23]; [@B1]; [@B20]). In this study, we utilized MALDI-TOF mass spectrometry to identify host proteins that can interact with Rta and affect Rta activation of the EBV lytic cycle. From the mass spectrometry results, we identified TRIM5α as an Rta-interacting protein (**Figure [1](#F1){ref-type="fig"}**). Considering that TRIM5α is a known E3 ubiquitin ligase ([@B41]), while Rta ubiquitination has also been reported to affect its transactivation capabilities ([@B43]), we therefore sought to confirm whether TRIM5α influences Rta ubiquitination, and if so, whether Rta transactivation ability is affected as a result. Our results also suggest that TRIM5α may be abundantly present in P3HR1 cells, as levels of TRIM5α were detectable by Coomassie blue staining of a 2-D polyacrylamide gel. Our previous studies identified cellular Rta-interacting proteins, such as MCAF1 and ATF2 ([@B9]; [@B22]), which were not detected by MALDI-TOF mass spectrometry analysis. It is likely that the amounts of these proteins binding to Rta are less than that of TRIM5α, causing the proteins to escape detection. In order to validate the interaction between Rta and TRIM5α, we conducted a GST-pulldown assay, and showed that GST-TRIM5α-glutathione-Sepharose beads pulled down His-Rta (**Figure [2A](#F2){ref-type="fig"}**, lane 5) via the N-terminal region in Rta and the N-terminal RING domain in TRIM5α (**Figure [4](#F4){ref-type="fig"}**). Conversely, anti-Rta antibody was also shown to coimmunoprecipitate HA-TRIM5α (**Figure [2B](#F2){ref-type="fig"}**, lanes 3 and 8). Confocal microscopy results revealed that Rta colocalizes with TRIM5α in the nuclei of P3HR1 cells after EBV lytic induction (**Figure [3](#F3){ref-type="fig"}**). Taken together, these results corroborate the mass spectrometry findings, and provide supporting evidence for Rta-TRIM5α interaction. Interestingly, previous studies have shown that TRIM5α primarily resides in the cytoplasm, so as to defend against incoming retroviral virions ([@B36]). We also examined the subcellular localization of GFP-TRIM5α and TRIM5α in 293T cells, and found that TRIM5α formed dots in the cytoplasm (data not shown). However, our findings suggest that the majority of TRIM5α is present in the nuclei of P3HR1 cells, rather than the cytoplasm (**Figure [3](#F3){ref-type="fig"}**). Whether this is an anomaly that exists only in P3HR1 or lymphocyte cells, or a response to activation of the viral lytic cycle by previously latent EBV in the cell nuclei remains to be determined. It has been reported that TRIM5α can shuttle between the cytoplasm and nucleus in a manner that is dependent on amino acids 60--93 in the N-terminal of TRIM5α, although there is no significant influence to the antiviral activity ([@B15]). Still, the factors driving TRIM5α shuttling have not been identified as yet, and it is possible that TRIM5α may relocate in response to different viral insults, via mechanisms that remain to be elucidated.

TRIM5α is known to act as an E3 ubiquitin ligase, and here we found that TRIM5α can promote Rta ubiquitination (**Figure [5A](#F5){ref-type="fig"}**). Introducing TRIM5α shRNA inhibits the levels of ubiquitinated Rta in 293T cells (**Figure [5B](#F5){ref-type="fig"}**). However, we were unable to detect the difference in the amounts of ubiquitinated Rta before and after the knockdown of TRIM5α in P3HR1 cells. EBV is known to express at least three deubiquitinases, including BSLF1, BPLF1, and BXLF1 ([@B32]; [@B34]). This may stabilize Rta, making the detection of its ubiquitination in P3HR1 cells more difficult. We also found that USP11, a deubiquitinase that acts against RNF4 activity ([@B19]), removes the ubiquitin chains on Rta efficiently (Chen et. al., unpublished results), suggesting that the ubiquitination of Rta is tightly regulated under physiological conditions. Additionally, overexpression of TRIM5α appears to hamper Rta transactivation of the EBV lytic cycle, as intracellular amounts of Rta, EA-D, BFRF3, and VCA viral lytic proteins in P3HR1 cells treated with sodium butyrate and TPA decreased with TRIM5α overexpression; moreover, expression of TRIM5α reduced the number of EBV virions produced by P3HR1 cells (**Figure [7](#F7){ref-type="fig"}**). In a transient transfection study, we showed that the ability of Rta to transactivate three EBV lytic promoters is negatively affected in a dose-dependent manner by enhanced expression of TRIM5α (**Figure [6](#F6){ref-type="fig"}**). Furthermore, the expression of TRIM5α shRNA significantly increased the number of EBV viral particles produced by P3HR1 cells treated with sodium butyrate and TPA (**Figure [7](#F7){ref-type="fig"}**). These results show that TRIM5α expression attenuates Rta ability to activate the transcription of EBV lytic genes and promote EBV lytic development, and suggests that the antiviral properties of TRIM5α may extend beyond retroviruses.

So far, only a few proteins, including NK-κB and hTERT, are known to decrease the lytic potential of EBV ([@B6]; [@B38]). Among these two proteins, NK-κB is known to inhibit EBV lytic transcription and replication ([@B5]), while hTERT disrupts the EBV lytic cycle via a mechanism that is as yet unclear ([@B38]). Our previous research indicated that RNF4 can target SUMO-2-Rta to enhance the ubiquitination of Rta, thereby inhibiting EBV lytic progression ([@B43]). Here, we report another cellular protein, TRIM5α, which also can play a negative role in hampering EBV lytic development. It is known that Rta is constitutively expressed, particularly in epithelial cells ([@B46]). The presence of TRIM5α may reduce Rta expression levels at this stage and allow the virus to be maintained in latency. Further research into the role of TRIM5α and its ability to influence EBV and other viral physiology may be warranted.

In summary, we demonstrate that an E3 ubiquitin ligase, TRIM5α, can interact in the cell nucleus with the EBV immediate-early protein, Rta. TRIM5α promotes Rta ubiquitination, and this subsequently disrupts Rta ability to transactivate EBV lytic genes. Overexpression of TRIM5α was found to reduce viral promoter activation and viral lytic gene expression in a dose-dependent manner. Moreover, TRIM5α reduced EBV virion production in P3HR1 cells treated with sodium butyrate and TPA to induce EBV lytic activation, while the application of TRIM5α shRNA significantly increased the production of EBV viral particles. Taken together, these results indicate that TRIM5α can hamper Rta transactivation via the promotion of Rta ubiquitination, and suggest that the antiviral properties of TRIM5α may not be limited to retroviruses.
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